Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 January 2018Website:
http://www.solidbio.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:02:50 GMTDividend
Analysts recommendations
Institutional Ownership
SLDB Latest News
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
Solid Biosciences (NASDAQ: SLDB) recently released their first quarter 2024 financial results, reporting an earnings per share of -64 cents.
Solid Biosciences is concentrating on advancing gene therapy for neuromuscular and cardiac disorders, with their primary focus being on a drug therapy for Duchenne muscular dystrophy (DMD) that is scheduled for testing in the second quarter of 2024. The company has recently received added funding from a private investment in public equity (PIPE), which has enhanced its risk-reward balance.
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
What type of business is Solid Biosciences?
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
What sector is Solid Biosciences in?
Solid Biosciences is in the Healthcare sector
What industry is Solid Biosciences in?
Solid Biosciences is in the Biotechnology industry
What country is Solid Biosciences from?
Solid Biosciences is headquartered in United States
When did Solid Biosciences go public?
Solid Biosciences initial public offering (IPO) was on 26 January 2018
What is Solid Biosciences website?
https://www.solidbio.com
Is Solid Biosciences in the S&P 500?
No, Solid Biosciences is not included in the S&P 500 index
Is Solid Biosciences in the NASDAQ 100?
No, Solid Biosciences is not included in the NASDAQ 100 index
Is Solid Biosciences in the Dow Jones?
No, Solid Biosciences is not included in the Dow Jones index
When was Solid Biosciences the previous earnings report?
No data
When does Solid Biosciences earnings report?
The next expected earnings date for Solid Biosciences is 08 November 2024